Flu Fighter Visterra Tops Up Series A Round With Cash From Gates
This article was originally published in The Pink Sheet Daily
To help push an antibody flu treatment into the clinic, the biotech has added $13 million from The Gates Foundation and others to bring total Series A funding to $26 million.
You may also be interested in...
The biotech plans to file an IND for its lead antibody candidate in seasonal and pandemic flu in early 2014. It also will optimize MIT research into dengue virus to find a clinical candidate to treat dengue fever.
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.